Cadrenal Therapeutics has appointed John P. Sharp as its interim chief financial officer, effective June 25, 2026. He succeeds Quang X. Pham, who ceased to serve as interim CFO on the same date. The transition was detailed in a regulatory filing submitted by the company.

John P. Sharp assumes the financial leadership role following the departure of Quang X. Pham. The filing did not provide specific reasons for the change in leadership or details regarding Pham's future role with the company.

The appointment of Sharp is intended to ensure continuity in the company's financial operations during the interim period. Cadrenal Therapeutics has not indicated how long the interim arrangement will last or if a search for a permanent CFO is underway.

Cadrenal Therapeutics announced that late-breaking clinical data on its first-in-class 12-lipoxygenase inhibitor, CAD-1005, has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH). The presentation highlights the clinical value potential of CAD-1005 for treating Heparin-Induced Thrombocytopenia (HIT), a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals.

The abstract, titled "12-lipoxygenase inhibition with VLX-1005 in heparin-induced thrombocytopenia," was selected by expert peer reviewers for inclusion in the session on clinical trials and breakthrough innovations. This marks the first-ever randomized, blinded, placebo-controlled trial in HIT, positioning the therapy as a Phase-3 ready candidate.

Key Details of the Presentation

Market Potential

The therapy addresses a significant unmet need in the HIT market, which carries a peak annual revenue potential of $2 billion. Cadrenal Therapeutics is advancing CAD-1005 as a late-stage novel therapy for life-threatening immune and thrombotic conditions.